Yahoo
NasdaqGM - Nasdaq Real Time Price USD

Kardigan, Inc. (KARD)

15.52 +1.66 (+11.98%)
At close: November 6 at 4:00:01 PM EST
15.70 +0.18 (+1.16%)
After hours: November 6 at 7:50:14 PM EST

Key Executives

Amounts are as of December 31, 2025 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
Name Title Pay Exercised Year Born
Mr. Tassos Anastasios E. Gianakakos M.Sc., MBA
Co-Founder, President, CEO & Chairman 5.8M -- 1973
Dr. Jay Edelberg M.D., Ph.D.
Co-founder & Chief Medical Officer 1.92M -- 1964
Ms. Brianne Puglisi
Chief Financial Officer 611.34k -- 1987
Dr. Bob McDowell Ph.D.
Co-founder & Scientific Advisor -- -- --
Dr. Leslie A. Leinwand Ph.D.
Co-Founder -- -- --
Dr. Elizabeth McNally M.D., Ph.D.
Co-Founder -- -- 1961
Mr. Donald Mackenzie Ph.D.
Chief Technical Operations Officer -- -- --
Mr. Clayton Robertson
Vice President of Investor Relations -- -- --
Mr. John B. Moriarty Jr., ESQ., J.D.
Chief Legal Officer & Corporate Secretary -- -- 1968
Ms. Emily Faucette
Chief Communications Officer -- -- --

Kardigan, Inc.

506 Carnegie Center Drive
Suite 201
Princeton, NJ 08540
United States
(415) 573-3220 https://www.kardigan.bio
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
241

Description

Kardigan, Inc. operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases. The company develops and provides a portfolio of medicines that target the underlying pathophysiology of cardiovascular diseases, including primary and secondary cardiomyopathies leading to heart failure. It utilizes a proprietary research and development platform that integrates AI-based tools, real-world clinical data, and cardiac-specific analytics to optimize clinical study design, patient screening, and efficacy tracking. The company incorporates Prolaio's cardiovascular data collection and analytics platform, which includes FDA-cleared algorithms and high-density patient data, to support drug development and clinical intelligence. The company engages in strategic in-licensing and acquisitions to expand its pipeline of targeted treatments. Kardigan serves biopharmaceutical companies, cardiovascular researchers, and healthcare providers in the cardiology sector. The company was formerly known as EnCarda, Inc. and changed its name to Kardigan, Inc. in December 2024. The company was founded in 2023 and is based in Princeton, New Jersey.

Corporate Governance

Kardigan, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

November 9, 2026 at 1:30 PM UTC

Kardigan, Inc. Earnings Date

Recent Events

November 6, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

September 30, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

August 11, 2026 at 12:00 AM UTC

10-Q: Periodic Financial Reports

June 23, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

June 17, 2026 at 12:00 AM UTC

S-8: Offering Registrations

May 26, 2026 at 12:00 AM UTC

S-1: Offering Registrations

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: